FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

773879000: Antineoplastic therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726859011 Antineoplastic therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726860018 Antineoplastic therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antineoplastic therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing only avapritinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing avapritinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing trastuzumab deruxtecan (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trastuzumab deruxtecan Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing trastuzumab deruxtecan in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only trastuzumab deruxtecan in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Enfortumab vedotin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing enfortumab vedotin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing enfortumab vedotin (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only enfortumab vedotin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only tazemetostat (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing tazemetostat in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing tazemetostat (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only tazemetostat in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing isatuximab (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Isatuximab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing isatuximab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only isatuximab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ibrutinib 140 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ibrutinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ibrutinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only ibrutinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ibrutinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely palbociclib 125 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Palbociclib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only palbociclib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing palbociclib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing palbociclib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely panobinostat (as panobinostat lactate) 15 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely panobinostat (as panobinostat lactate) 10 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ixazomib (as ixazomib citrate) 4 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ixazomib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ixazomib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely panobinostat (as panobinostat lactate) 20 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ixazomib (as ixazomib citrate) 3 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ixazomib (as ixazomib citrate) 2.3 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cabozantinib (as cabozantinib s-malate) 20 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only cabozantinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing cabozantinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing cabozantinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Cabozantinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely palbociclib 75 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely palbociclib 100 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cabozantinib (as cabozantinib s-malate) 80 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only durvalumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Durvalumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing durvalumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing durvalumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Encorafenib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only encorafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing encorafenib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing encorafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing selumetinib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Selumetinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing selumetinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only selumetinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely selumetinib 25 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely selumetinib 10 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pemigatinib 4.5 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pemigatinib 9 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pemigatinib 13.5 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pemigatinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pemigatinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pemigatinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pemigatinib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely tucatinib 50 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely tucatinib 150 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only tucatinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing tucatinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Tucatinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing tucatinib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sacituzumab govitecan (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Sacituzumab govitecan Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sacituzumab govitecan in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only sacituzumab govitecan in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only olaparib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely olaparib 150 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely olaparib 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing olaparib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Olaparib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing olaparib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only niraparib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Niraparib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing niraparib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing niraparib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Rucaparib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only rucaparib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing rucaparib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing rucaparib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing nivolumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only nivolumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Nivolumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing nivolumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ipilimumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only ipilimumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ipilimumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ipilimumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only atezolizumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing atezolizumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing atezolizumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Atezolizumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier

Start Page 2 of 26 Next End

This concept is not in any reference sets

Back to Start